LAFAYETTE, La. - Although she found that the trial testimony for a former Eli Lilly and Co. executive was suspect, the Louisiana federal judge overseeing the Actos bladder cancer multidistrict litigation on June 11 denied plaintiffs' motion to sanction Lilly for "contumacious conduct" and perjury (In Re: Actos [Pioglitazone] Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al., No. 6:12-64, W.D. La.).